# Allergy Therapeutics Plc to Present at Jefferies 2017 London Healthcare Conference

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-plc-present-jefferies-2017-london-healthcare-conference/412739745
- Published: 2017-11-13T07:09:54+00:00
- Author: Giles Arbor

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated specialty pharmaceutical group specialising in allergy vaccines,
announced today that Manuel Llobet, Chief Executive Officer, will be presenting 
at the Jefferies 2017 Healthcare Conference in London, on Wednesday 15 November 
at 13:20 GMT.

Allergy Therapeutics is an international specialty pharmaceutical group focussed
on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines
that have the potential to cure disease. The Group sells proprietary and third party
products from its subsidiaries in nine major European countries and via distribution
agreements in an additional ten countries. Its broad pipeline of products in clinical
development include vaccines for grass, tree and house dust mite, and peanut allergy
vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham,
Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of
state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group,
which has achieved double digit compound annual growth since formation, employs 
c.500 employees and is listed on the London Stock Exchange

Share on:
